- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00758082
Reinforcement of the Impact of a Functional Insulin Therapy Training Course by Telemonotoring With a PDA-phone in Type 1 Diabetic Patients. The TELFIT Study Patients (TELFIT)
Reinforcement of the Impact of a Functional Insulin Therapy Training Course by Telemonotoring With a PDA-phone in Type 1 Diabetic Patients. The TELFIT Study
TELFIT is a monocenter, controlled, randomised trial. It focuses on type 1 diabetes patients that have attended a functional insulin therapy training course. The Primary objective of the TELFIT study is to evaluate whether a PDA with telemonitoring by phone reinforces the effects of the functional insulin therapy training course as compared with conventional care.
Main judgment criteria: comparison of HbA1c means between M0 (start) and M3(3 months)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Grenoble, France, 38043
- University Hospital Grenoble
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 1 diabetes mellitus for ≥ 6 months or more
- Age > 18 year old
- The patient has attended a functional insulin therapy class or workshop
- Insulin basal-bolus therapy for at least 6 months. At inclusion, patients should be treated either with a long-acting insulin and insulin rapid analog before each meal, or with rapid insulin analog delivered with a pump
- Ability to understand how the PDA-phone works and ability to use it
- Social Security membership or benefit from Social Security
- Patients equipped with a memory blood glucose monitor
- Informed consent, with a signed and approved form
Exclusion Criteria:
- Underage patient, major patient under guardianship or protected by the Law
- Patient with any unstable associated evolutive pathology that could cause a diabetes imbalance within the coming year
- Change in diabetes treatment within the 3 months before inclusion or planned during the study
- Patient who needs a more frequent diabetic follow-up than in the protocol (especially severe or evolving complication due to diabetes)
- Patient attending another education program within the 3 months before inclusion or planning to attend one during the study
- Patient with toxicomania, alcoholism or psychological troubles that could impact the study
- Type-2-diabetic patient
- Patient who doesn't need strict metabolic objectives
- Pregnant or possibly pregnant woman
- Person with no freedom (prisoner)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
Patients will have face to face visits at 3 months and no PDA-phone.
Patients will record glycemia on paper support
|
Patients will have face to face visits at 3 months and no PDA-phone.
Patients will record glycemia on paper support.
|
Experimental: 2
PDA-phone + phone consultations + standard visit at 3 months
|
Patients will received PDA-phone + a telephone follow up + standard visit at 3 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Comparison of HbA1c means
Time Frame: M0 (start) and M3 (3 months)
|
M0 (start) and M3 (3 months)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference between theoretical insulin dose and actual dose, one week before the 3-month reevaluation session
Time Frame: M0 (start) and M3 (3 months)
|
M0 (start) and M3 (3 months)
|
DHP scale of quality of life and satisfaction dimension of the DQOL questionnaire
Time Frame: M0 (start) and M3 (3 months)
|
M0 (start) and M3 (3 months)
|
Time spent by physicians and nurses in the different groups
Time Frame: M0 (start) and M3 (3 months)
|
M0 (start) and M3 (3 months)
|
Weight changes during the 3-month period
Time Frame: M0 (start) and M3 (3 months)
|
M0 (start) and M3 (3 months)
|
Number of hypoglycemias (moderate and severe) during the 3-month period
Time Frame: M0 (start) and M3 (3 months)
|
M0 (start) and M3 (3 months)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Pierre Y Benhamou, PhD, University Hospital, Grenoble
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2008-A00389-46
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on paper support
-
University of FloridaNational Institutes of Health (NIH); International Centre for Diarrhoeal Disease... and other collaboratorsCompleted
-
University of FloridaRecruitingTelemedicine | PediatricsHaiti
-
Yonsei UniversityCompletedBreast NeoplasmsKorea, Republic of
-
University of Illinois at ChicagoTerminated
-
Johns Hopkins UniversityCompleted
-
Stanford UniversityResurrection Medical CenterCompletedBlister of FootUnited States
-
Stanford UniversityUniversity of California, DavisCompleted
-
Maria Isabel FernandezCompleted
-
University of ManitobaUnknown
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompleted